Decision trees to evaluate the risk of developing multiple sclerosis.
decision trees
human leukocyte antigen
immunogenetic risk markers
likelihood of multiple sclerosis development
machine learning
multiple classifier
multiple sclerosis
Journal
Frontiers in neuroinformatics
ISSN: 1662-5196
Titre abrégé: Front Neuroinform
Pays: Switzerland
ID NLM: 101477957
Informations de publication
Date de publication:
2023
2023
Historique:
received:
27
06
2023
accepted:
28
07
2023
medline:
31
8
2023
pubmed:
31
8
2023
entrez:
31
8
2023
Statut:
epublish
Résumé
Multiple sclerosis (MS) is a persistent neurological condition impacting the central nervous system (CNS). The precise cause of multiple sclerosis is still uncertain; however, it is thought to arise from a blend of genetic and environmental factors. MS diagnosis includes assessing medical history, conducting neurological exams, performing magnetic resonance imaging (MRI) scans, and analyzing cerebrospinal fluid. While there is currently no cure for MS, numerous treatments exist to address symptoms, decelerate disease progression, and enhance the quality of life for individuals with MS. This paper introduces a novel machine learning (ML) algorithm utilizing decision trees to address a key objective: creating a predictive tool for assessing the likelihood of MS development. It achieves this by combining prevalent demographic risk factors, specifically gender, with crucial immunogenetic risk markers, such as the alleles responsible for human leukocyte antigen (HLA) class I molecules and the killer immunoglobulin-like receptors (KIR) genes responsible for natural killer lymphocyte receptors. The study included 619 healthy controls and 299 patients affected by MS, all of whom originated from Sardinia. The gender feature has been disregarded due to its substantial bias in influencing the classification outcomes. By solely considering immunogenetic risk markers, the algorithm demonstrates an ability to accurately identify 73.24% of MS patients and 66.07% of individuals without the disease. Given its notable performance, this system has the potential to support clinicians in monitoring the relatives of MS patients and identifying individuals who are at an increased risk of developing the disease.
Identifiants
pubmed: 37649987
doi: 10.3389/fninf.2023.1248632
pmc: PMC10465164
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1248632Informations de copyright
Copyright © 2023 Pasella, Pisano, Cannas, Fanni, Cocco, Frau, Lai, Mocci, Littera and Giglio.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer MF declared a past co-authorship with the author EC to the handling editor AF-C.
Références
J Neurol. 2002 Feb;249(2):152-63
pubmed: 11985380
J Neuroimmunol. 2014 Apr 15;269(1-2):52-5
pubmed: 24529855
Curr Protoc Immunol. 2018 Apr;121(1):e47
pubmed: 30040219
Immunity. 1997 Dec;7(6):753-63
pubmed: 9430221
Front Immunol. 2011 Oct 04;2:48
pubmed: 22566838
Nat Rev Neurol. 2010 Mar;6(3):156-66
pubmed: 20157307
Cell J. 2017 Apr-Jun;19(1):1-10
pubmed: 28367411
Eur J Neurol. 2019 Jan;26(1):27-40
pubmed: 30300457
PLoS One. 2007 Jul 25;2(7):e664
pubmed: 17653284
Cell. 2018 Nov 29;175(6):1679-1687.e7
pubmed: 30343897
Annu Rev Immunol. 1991;9:493-525
pubmed: 1910687
Sci Adv. 2016 Jun 17;2(6):e1501678
pubmed: 27386562
Brain. 2013 Sep;136(Pt 9):2657-76
pubmed: 22734127
Biomedicines. 2022 Aug 28;10(9):
pubmed: 36140203
Nat Rev Neurol. 2017 Jan;13(1):25-36
pubmed: 27934854
J Neurol Neurosurg Psychiatry. 2019 Nov;90(11):1193-1200
pubmed: 31217172
Nat Rev Immunol. 2015 Sep 15;15(9):545-58
pubmed: 26250739
Int J Mol Sci. 2021 Mar 09;22(5):
pubmed: 33803217
Neurology. 2014 Sep 9;83(11):1022-4
pubmed: 25200713
Tissue Antigens. 1992 Oct;40(4):165-74
pubmed: 1471143
Front Neurosci. 2021 May 11;15:614528
pubmed: 34045940
Immunogenetics. 2019 Mar;71(3):161-170
pubmed: 30215098
Front Genet. 2022 Jun 08;13:913196
pubmed: 35754823
Immunotherapy. 2012 May;4(5):529-47
pubmed: 22642335
Nat Rev Immunol. 2003 Dec;3(12):973-83
pubmed: 14647479
Radiol Artif Intell. 2019 Jan 30;1(1):e180031
pubmed: 33937783
Nat Rev Cancer. 2018 Aug;18(8):500-510
pubmed: 29777175
Front Immunol. 2021 Jul 06;12:680480
pubmed: 34295330
Neurology. 1996 Apr;46(4):907-11
pubmed: 8780061
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Antioxid Redox Signal. 2013 Dec 20;19(18):2286-334
pubmed: 23473637
J Clin Invest. 2012 Apr;122(4):1180-8
pubmed: 22466660
Genom Data. 2016 Sep 28;10:75-78
pubmed: 27747156
Immunol Rev. 2012 Jul;248(1):87-103
pubmed: 22725956
Lancet. 2008 Oct 25;372(9648):1502-17
pubmed: 18970977
Am J Manag Care. 2013 Feb;19(2 Suppl):S15-20
pubmed: 23544716
Dis Markers. 2019 Nov 6;2019:1409069
pubmed: 31781296
Front Immunol. 2019 May 28;10:1179
pubmed: 31231370
Future Healthc J. 2019 Jun;6(2):94-98
pubmed: 31363513
Front Immunol. 2017 Apr 18;8:425
pubmed: 28458668
Front Immunol. 2021 Oct 06;12:728677
pubmed: 34691035
Ann Neurol. 2009 Jun;65(6):658-66
pubmed: 19630074
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Nature. 2011 Aug 10;476(7359):214-9
pubmed: 21833088
Science. 1988 May 20;240(4855):1003-9
pubmed: 3368786
Nat Commun. 2019 May 20;10(1):2236
pubmed: 31110181
Brain Commun. 2023 Feb 22;5(2):fcad041
pubmed: 37006331
Front Neurol. 2022 Feb 08;12:761973
pubmed: 35211072
Comput Biol Med. 2021 May;132:104337
pubmed: 33773193
Adv Rheumatol. 2020 Jan 10;60(1):8
pubmed: 31924272
Lancet. 2017 Apr 1;389(10076):1336-1346
pubmed: 27889190
Hum Immunol. 2002 Apr;63(4):271-80
pubmed: 12039408
Annu Rev Immunol. 2015;33:787-821
pubmed: 25706097
J Neurol. 2022 Sep;269(9):5127-5135
pubmed: 35604465
Clin Med (Lond). 2017 Dec;17(6):545-551
pubmed: 29196356
J Neuroimmunol. 2010 Dec 15;229(1-2):232-7
pubmed: 20826009
Mult Scler. 2019 Jan;25(1):23-30
pubmed: 29111883
J Clin Invest. 2004 Mar;113(6):788-94
pubmed: 15067307
Mol Immunol. 2011 Sep;48(15-16):1896-902
pubmed: 21665278
Clin Med Res. 2003 Jan;1(1):57-60
pubmed: 15931287
Sci Transl Med. 2015 Jul 15;7(296):296ra112
pubmed: 26180102
N Engl J Med. 2011 Dec 8;365(23):2188-97
pubmed: 22150037
Brain. 2021 Aug 17;144(7):2038-2046
pubmed: 33704407
J Autoimmun. 2015 Nov;64:13-25
pubmed: 26142251
Schweiz Arch Neurol Psychiatr (1985). 1986;137(4):5-13
pubmed: 2428106
Front Immunol. 2021 Jul 07;12:665718
pubmed: 34305896
Science. 2019 Sep 27;365(6460):
pubmed: 31604244
N Engl J Med. 2018 Jan 11;378(2):169-180
pubmed: 29320652
Lancet Neurol. 2010 May;9(5):520-32
pubmed: 20398859
Neuroimage Clin. 2022;35:103065
pubmed: 35661470
Curr Top Microbiol Immunol. 2015;390(Pt 1):151-209
pubmed: 26424647
BMJ Health Care Inform. 2021 Apr;28(1):
pubmed: 33853863
Oncoimmunology. 2017 Feb 6;6(2):e1171447
pubmed: 28344859
Cancers (Basel). 2021 Jul 27;13(15):
pubmed: 34359667
Neuropsychiatr Dis Treat. 2018 Apr 23;14:1093-1099
pubmed: 29719400
Cold Spring Harb Perspect Med. 2018 Sep 4;8(9):
pubmed: 29358317
Nat Rev Neurol. 2019 Jun;15(6):329-342
pubmed: 31000816
PLoS One. 2019 Dec 17;14(12):e0226615
pubmed: 31846493
PLoS One. 2021 Mar 22;16(3):e0246157
pubmed: 33750973